Every 8-K that ZOETIS INC. (ZTS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ZTS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ZTS filings page.
Zoetis Inc. has appointed James (Jay) Saccaro as Executive Vice President, Chief Financial Officer and Chief Operating Officer, effective August 17, 2026. He will serve as the company’s principal financial officer and principal accounting officer, leading global finance and overseeing Global Manufacturing and Supply.
Under an offer letter dated July 31, 2026, Mr. Saccaro will receive a $1,000,000 annual base salary, a target annual bonus equal to 100% of base salary (with his 2026 bonus paid at target and prorated), and an annual long-term incentive opportunity of $5,000,000 in performance stock units, restricted stock units, and stock options. He is eligible for the Executive Severance Plan, relocation assistance, and standard executive benefits. He will also receive a one-time make-whole RSU award of $6,250,000, vesting in three equal annual installments, and a one-time make-whole cash award of $1,250,000 subject to repayment if his employment ends under certain circumstances within his first year.
Current CFO Wetteny Joseph will transition from Executive Vice President and Chief Financial Officer after August 16, 2026 to a non-officer role and will serve as a Special Advisor to the CEO on financial matters until early 2027. Until the earlier of February 28, 2027 or a mutually agreed termination date, he will continue his current salary, benefits, and equity vesting and remain eligible for a 2026 annual incentive award. Upon his termination date, he will receive separation benefits under Section 3.1 of the Executive Severance Plan, with equity treated as upon a “Restructuring Event.” The company states that his departure is not due to any disagreement on operations, policies, practices, accounting, or controls.
Zoetis Inc. reported second-quarter 2026 revenue of $2,468 million, essentially flat versus the prior year and down 1% on an organic operational basis. Net income was $691 million, or $1.65 per diluted share, down 5% and up 1%, respectively, on a reported basis. Adjusted net income was $781 million and adjusted diluted EPS $1.87, down 1% and up 5% on a reported basis and down 2% and up 4% on an organic operational basis.
U.S. revenue fell 7% to $1,266 million, with companion animal sales down 11% amid softer clinic demand, price sensitivity and generic competition, partly offset by 23% growth in U.S. livestock. International revenue rose 8% to $1,173 million, driven by parasiticides, diagnostics and new osteoarthritis monoclonal antibody launches.
Zoetis updated its 2026 outlook, now guiding to revenue of $9.120–$9.320 billion (organic operational revenue growth of (3)% to (1)%), reported net income of $2.330–$2.380 billion, adjusted net income of $2.570–$2.620 billion (organic operational growth of (9)% to (5)%), reported diluted EPS of $5.55–$5.65 and adjusted diluted EPS of $6.15–$6.25, compared with prior adjusted EPS guidance of $6.85–$7.00.
Zoetis Inc. reported results of its 2026 Annual Meeting of Shareholders and a Board change. Effective May 20, 2026, director Louise M. Parent retired from the Board in line with the company’s director retirement policy.
Shareholders representing 379,034,516 shares, or 90.13% of voting power as of the March 27, 2026 record date, were present, establishing a quorum. All twelve director nominees were elected for one-year terms, and shareholders approved, on a non-binding basis, the executive compensation program and chose to hold this advisory vote every year.
Shareholders also ratified KPMG LLP as independent registered public accounting firm for the year ending December 31, 2026. A shareholder proposal to permit shareholder action by written consent did not receive sufficient support and was not approved.
Zoetis Inc. announced that its Board of Directors declared a cash dividend of $0.53 per share for the third quarter of 2026. The dividend will be paid on September 1, 2026 to shareholders of record as of the close of business on July 20, 2026. This reflects ongoing cash returns to common stockholders through regular dividend payments.
Zoetis Inc. reported first quarter 2026 revenue of $2.262 billion, up 3% from a year earlier, with organic operational revenue flat. Net income was $601 million, or $1.42 per diluted share, with earnings per share up 6% on a reported basis.
Adjusted net income was $646 million and adjusted diluted EPS was $1.53, up 2% and 9% respectively, and 1% on an organic operational basis. U.S. revenue fell 8% to $1.09 billion amid weaker companion animal demand and greater competition, while International revenue rose 17% to $1.149 billion with strong livestock growth.
Zoetis updated 2026 guidance to revenue of $9.680–$9.960 billion, adjusted net income of $2.870–$2.950 billion and adjusted diluted EPS of $6.85–$7.00, implying low- to mid-single-digit organic operational growth. Management highlighted a robust innovation pipeline and the planned acquisition of Neogen’s animal genomics business in the second half of 2026.
Zoetis Inc. reported modest growth for the fourth quarter and full year 2025 and issued guidance for 2026. Fourth quarter revenue was $2.4 billion, up 3% year over year, with net income of $603 million, or $1.37 per diluted share. Adjusted net income was $648 million, or $1.48 per diluted share.
For full year 2025, revenue reached $9.5 billion, up 2%, while net income rose to $2.7 billion, or $6.02 per diluted share. Adjusted net income was $2.8 billion, or $6.41 per diluted share, reflecting 6% growth. International revenue benefited from timing changes related to an expected fiscal year alignment, adding about 2.5% to 3.5% to fourth quarter International sales.
The company highlighted approvals for its long-acting osteoarthritis pain monoclonal antibodies Lenivia and Portela in Canada and the EU, and the acquisition of Veterinary Pathology Group in the UK and Ireland. For 2026, Zoetis guided to revenue of $9.825 billion to $10.025 billion and adjusted diluted EPS of $7.00 to $7.10, implying 3% to 5% organic operational revenue growth.
Zoetis Inc. declared a quarterly dividend of $0.53 per share for the second quarter of 2026. The dividend will be paid on June 2, 2026 to shareholders of record as of the close of business on April 20, 2026. The company also noted that the related information is being furnished under Regulation FD and not treated as filed for liability purposes.
Zoetis Inc. completed a private offering of $2.0 billion of 0.25% Convertible Senior Notes due 2029. The notes are senior unsecured, pay interest semiannually and are convertible into cash and, at Zoetis’ election, cash, shares or a combination based on an initial conversion rate of 6.7476 shares per $1,000 principal amount, equal to an initial conversion price of about $148.20 per share, a 22.5% premium to the last reported share price on December 15, 2025.
Zoetis expects net proceeds of about $1,969.6 million, allocating approximately $186.6 million to capped call transactions, about $248.0 million to repurchase roughly 2.1 million shares in concurrent private transactions, and about $1,535.0 million for additional share repurchases under its existing $6 billion authorization, which it expects to complete by no later than the first quarter of 2026.
The capped call agreements cover about 13.5 million shares, with strike and cap prices tied to the notes’ conversion economics, and are expected generally to reduce potential dilution or offset cash payments above principal if the notes are converted. Zoetis also obtained a waiver under its revolving credit facility that explicitly permits early conversions of the notes pursuant to their terms.
Zoetis Inc. announced a cash dividend for its common shareholders. The company declared a dividend of $0.53 per share for the first quarter of 2026. This dividend will be paid on March 3, 2026 to shareholders who are on record as owning Zoetis common stock at the close of business on January 20, 2026. The announcement was furnished as a Regulation FD disclosure, meaning it is intended to provide broad, fair access to this information for all investors.
Zoetis Inc. announced that it will host an Innovation Webcast at 8:30 a.m. ET on December 2, 2025. The webcast will feature a company presentation focused on its innovation-related topics in animal health. The presentation materials for this event are provided as an exhibit to the report, giving investors and stakeholders access to the same information shared during the webcast.
Zoetis Inc. (ZTS) furnished an update on its business by reporting third-quarter 2025 results and full-year 2025 guidance. The company announced these details in a press release dated November 4, 2025, which is provided as Exhibit 99.1.
The disclosure is presented under Item 2.02: Results of Operations and Financial Condition and is furnished, not filed, under the Exchange Act. This means it is not subject to Section 18 liabilities and is not incorporated by reference unless specifically stated. The filing confirms Zoetis’ common stock trades on the NYSE under the symbol ZTS.
Zoetis (ZTS) appointed Stephanie Tilenius to its Board of Directors, effective December 1, 2025. The Board will increase from 12 to 13 members on that date.
The company states the appointment was not made pursuant to any third‑party arrangement and notes no related party transactions with Ms. Tilenius since the beginning of the last fiscal year. She will be eligible under Zoetis’ non‑employee director compensation program outlined in its 2025 proxy. Zoetis will enter into its standard indemnification agreement with her, and a press release announcing the appointment was issued on October 28, 2025.
Zoetis Inc. declared a cash dividend of $0.50 per share for the fourth quarter of 2025. The dividend will be paid on December 2, 2025 to shareholders who are on record as of the close of business on October 31, 2025. This reflects the company’s ongoing practice of returning cash to common stock holders through regular quarterly dividends.
Zoetis Inc. filed an 8-K reporting a material event: a Revolving Credit Agreement dated August 27, 2025 among Zoetis, the lenders, the issuing banks and JPMorgan Chase Bank, N.A. as administrative agent. The document identifies the agreement date and parties and includes an interactive cover page in the Inline XBRL file. The filing is signed by Roxanne Lagano, Executive Vice President, General Counsel and Corporate Secretary. The filing text does not disclose the credit facility’s economic terms, commitment size, maturity, covenants, or borrowing details.
Zoetis Inc. disclosed that it entered into an Underwriting Agreement on August 11, 2025 for a public debt offering of two senior note tranches. The company is issuing $850,000,000 aggregate principal amount of 4.150% Senior Notes due 2028 and $1,000,000,000 aggregate principal amount of 5.000% Senior Notes due 2035. These Notes are issued under Zoetis’s existing indenture with Deutsche Bank Trust Company Americas, as supplemented on August 18, 2025, and are registered under an effective Form S-3 shelf registration statement. Related agreements, indentures, note forms, and legal opinions are filed as exhibits.